165 related articles for article (PubMed ID: 27224851)
1. Bortezomib for the prevention and treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Al-Homsi AS; Feng Y; Duffner U; Al Malki MM; Goodyke A; Cole K; Muilenburg M; Abdel-Mageed A
Exp Hematol; 2016 Sep; 44(9):771-777. PubMed ID: 27224851
[TBL] [Abstract][Full Text] [Related]
2. Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study.
Al-Homsi AS; Cole K; Bogema M; Duffner U; Williams S; Mageed A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1315-20. PubMed ID: 25765556
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Complement Alternative Pathway Permits Graft Versus Leukemia Activity while Preventing Graft Versus Host Disease.
Nguyen H; Alawieh A; Bastian D; Kuril S; Dai M; Daenthanasanmak A; Zhang M; Iamsawat S; Schutt SD; Wu Y; Sleiman MM; Shetty A; Atkinson C; Sun S; Varela JC; Tomlinson S; Yu XZ
Clin Cancer Res; 2020 Jul; 26(13):3481-3490. PubMed ID: 31919135
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Harnessing dendritic cells to improve allogeneic hematopoietic cell transplantation outcome.
Hashimoto D; Merad M
Semin Immunol; 2011 Feb; 23(1):50-7. PubMed ID: 21316261
[TBL] [Abstract][Full Text] [Related]
6. Ixazomib suppresses human dendritic cell and modulates murine graft-versus-host disease in a schedule-dependent fashion.
Al-Homsi AS; Goodyke A; Cole K; Muilenburg M; McLane M; Abdel-Mageed S; Feng Y
Exp Hematol; 2017 Apr; 48():50-57. PubMed ID: 28007655
[TBL] [Abstract][Full Text] [Related]
7. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
[TBL] [Abstract][Full Text] [Related]
8. TIGIT-Fc alleviates acute graft-versus-host disease by suppressing CTL activation via promoting the generation of immunoregulatory dendritic cells.
Zhang D; Hu W; Xie J; Zhang Y; Zhou B; Liu X; Zhang Y; Su Y; Jin B; Guo S; Zhuang R
Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):3085-3098. PubMed ID: 29960041
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib regulates the chemotactic characteristics of T cells through downregulation of CXCR3/CXCL9 expression and induction of apoptosis.
Liu W; Ren HY; Dong YJ; Wang LH; Yin Y; Li Y; Qiu ZX; Cen XN; Shi YJ
Int J Hematol; 2012 Dec; 96(6):764-72. PubMed ID: 23179902
[TBL] [Abstract][Full Text] [Related]
10. Novel targets in the treatment of chronic graft-versus-host disease.
Im A; Hakim FT; Pavletic SZ
Leukemia; 2017 Mar; 31(3):543-554. PubMed ID: 27899803
[TBL] [Abstract][Full Text] [Related]
11. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
Fowler DH; Gress RE
Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
[TBL] [Abstract][Full Text] [Related]
12. Calcineurin and mTOR Inhibitor-Free Post-Transplantation Cyclophosphamide and Bortezomib Combination for Graft-versus-Host Disease Prevention after Peripheral Blood Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I/II Study.
Al-Homsi AS; Cole K; Muilenburg M; Goodyke A; Abidi M; Duffner U; Williams S; Parker J; Abdel-Mageed A
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1651-1657. PubMed ID: 28549771
[TBL] [Abstract][Full Text] [Related]
13. Umbilical cord blood-derived mesenchymal stem cells ameliorate graft-versus-host disease following allogeneic hematopoietic stem cell transplantation through multiple immunoregulations.
Wu QL; Liu XY; Nie DM; Zhu XX; Fang J; You Y; Zhong ZD; Xia LH; Hong M
J Huazhong Univ Sci Technolog Med Sci; 2015 Aug; 35(4):477-484. PubMed ID: 26223913
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells and acute graft-versus-host disease after allogeneic stem cell transplantation.
Mohty M
Leuk Lymphoma; 2007 Sep; 48(9):1696-701. PubMed ID: 17786704
[TBL] [Abstract][Full Text] [Related]
15. Preventive azithromycin treatment reduces noninfectious lung injury and acute graft-versus-host disease in a murine model of allogeneic hematopoietic cell transplantation.
Radhakrishnan SV; Palaniyandi S; Mueller G; Miklos S; Hager M; Spacenko E; Karlsson FJ; Huber E; Kittan NA; Hildebrandt GC
Biol Blood Marrow Transplant; 2015 Jan; 21(1):30-8. PubMed ID: 25445642
[TBL] [Abstract][Full Text] [Related]
16. CD45RA depletion in HLA-mismatched allogeneic hematopoietic stem cell transplantation for primary combined immunodeficiency: A preliminary study.
Touzot F; Neven B; Dal-Cortivo L; Gabrion A; Moshous D; Cros G; Chomton M; Luby JM; Terniaux B; Magalon J; Picard C; Blanche S; Fischer A; Cavazzana M
J Allergy Clin Immunol; 2015 May; 135(5):1303-9.e1-3. PubMed ID: 25282016
[TBL] [Abstract][Full Text] [Related]
17. Helper T-cell differentiation in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Fu J; Heinrichs J; Yu XZ
Arch Immunol Ther Exp (Warsz); 2014 Aug; 62(4):277-301. PubMed ID: 24699629
[TBL] [Abstract][Full Text] [Related]
18. Total lymphoid irradiation for graft-versus-host disease protection.
Kohrt H; Lowsky R
Curr Opin Oncol; 2009 Jun; 21 Suppl 1():S23-6. PubMed ID: 19561409
[TBL] [Abstract][Full Text] [Related]
19. Depletion of alloreactive T-cells in vitro using the proteasome inhibitor bortezomib preserves the immune response against pathogens.
Blanco B; Sánchez-Abarca LI; Caballero-Velázquez T; Santamaría C; Inogés S; Pérez-Simón JA
Leuk Res; 2011 Oct; 35(10):1412-5. PubMed ID: 21658766
[TBL] [Abstract][Full Text] [Related]
20. Immunological effects in patients with steroid-refractory graft-versus-host disease following treatment with basiliximab, a CD25 monoclonal antibody.
Chakupurakal G; García-Márquez MA; Shimabukuro-Vornhagen A; Theurich S; Holtick U; Hallek M; Scheid C; von Bergwelt-Baildon M
Eur J Haematol; 2016 Aug; 97(2):121-7. PubMed ID: 26492560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
